Iloprost Colonis Pharma (Iloprost Trometamol)

Iloprost is a selective agonist of the prostacyclin (IP) receptor. Activation of this receptor increases cyclic AMP within vascular smooth‑muscle cells, causing potent vasodilation of pulmonary and systemic arteries. The same signaling pathway also inhibits platelet aggregation, which together improve oxygen delivery to the lungs and peripheral tissues.

The specific dose and infusion rate of Iloprost are determined by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. Dosing is individualized and may be adjusted during treatment to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for Iloprost during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risks and benefits with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Iloprost belongs to the prostacyclin class, offering direct vasodilation and antiplatelet effects. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, it provides rapid hemodynamic improvement but requires intravenous infusion. Its profile is useful for patients who need immediate pulmonary pressure reduction or who cannot tolerate oral agents.

Iloprost should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than a few hours and return the product to refrigeration promptly.

Iloprost is administered by intravenous infusion, typically using an infusion pump to deliver a controlled rate. The infusion is given over a defined period, often several minutes to an hour, under continuous monitoring of blood pressure, heart rate, and clinical response. Administration is performed by qualified healthcare personnel.

The most serious adverse events include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, myocardial ischemia, and life‑threatening arrhythmias. Patients should be closely monitored during infusion, and any signs of sudden blood pressure drop, chest pain, excessive bleeding, or abnormal heart rhythm require immediate medical attention.

Iloprost is contraindicated in patients with active uncontrolled bleeding, severe hypotension, recent myocardial infarction, known hypersensitivity to iloprost or any component of the formulation, and in those for whom a reliable intravenous access cannot be maintained. Clinicians must evaluate each patient’s medical history before initiating therapy.